GSK/$GSK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Primary listing
NYSE
Employees
68,629
Headquarters
Website
GSK Metrics
BasicAdvanced
$82B
36.45
$1.12
0.29
$1.58
4.19%
Price and volume
Market cap
$82B
Beta
0.29
52-week high
$43.23
52-week low
$31.72
Average daily volume
3.6M
Dividend rate
$1.58
Financial strength
Current ratio
0.867
Quick ratio
0.555
Long term debt to equity
106.618
Total debt to equity
120.9
Dividend payout ratio (TTM)
72.80%
Interest coverage (TTM)
10.25%
Profitability
EBITDA (TTM)
12,597.109
Gross margin (TTM)
71.69%
Net profit margin (TTM)
10.82%
Operating margin (TTM)
20.13%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
$623,680
Management effectiveness
Return on assets (TTM)
6.78%
Return on equity (TTM)
28.33%
Valuation
Price to earnings (TTM)
36.447
Price to revenue (TTM)
3.882
Price to book
4.11
Price to tangible book (TTM)
-8.31
Price to free cash flow (TTM)
25.347
Free cash flow yield (TTM)
3.95%
Free cash flow per share (TTM)
1.611
Dividend yield (TTM)
3.87%
Forward dividend yield
4.19%
Growth
Revenue change (TTM)
0.59%
Earnings per share change (TTM)
-15.48%
3-year revenue growth (CAGR)
4.37%
10-year revenue growth (CAGR)
3.09%
3-year earnings per share growth (CAGR)
-9.68%
10-year earnings per share growth (CAGR)
-10.43%
3-year dividend per share growth (CAGR)
-9.94%
10-year dividend per share growth (CAGR)
-4.52%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Bulls say / Bears say
Following a 6% year-on-year uplift in Q2 turnover to nearly £8 billion and adjusted earnings of 46.5 pence per share, GSK said it now expects full-year sales and profits at the top end of its 2025 forecasts. (Reuters)
GSK signed a $1 billion deal for exclusive rights to develop and commercialize Janssen’s hepatitis B therapy, strengthening its infectious disease pipeline amid patent expiry risks. (Reuters)
GSK applied to the EMA to expand its RSV vaccine Arexvy’s use to adults aged 18–49, potentially opening a new market segment and improving competitive positioning against Pfizer and Moderna. (Reuters)
GSK shares fell over 6% after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, threatening peak sales of over £3 billion previously projected. (Reuters)
In Q1 2025, GSK’s vaccine sales declined 6% to £2.1 billion, with its RSV shot Arexvy underperforming at just £0.1 billion, signaling continued pressure on its vaccines segment. (Reuters)
Analysts forecast GSK will reach only £34 billion in revenue by 2031—15% shy of management’s £40 billion target—raising concerns that the company may pursue value-dilutive M&A to bridge the gap. (Reuters Breakingviews)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct9
GSK
DividendPayment
$0.428118Per share
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $82B as of September 15, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 36.45 as of September 15, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $1.58204 and the yield is 4.19%. GSK has a payout ratio of 72.8% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment is scheduled for October 09, 2025.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.